Despite of a significant reduction in overall dosage in the BAY-I cohort (1440 mg/Kg total dose for BAY-I vs. 2100 mg/kg total dose for BAY-D), both BAY-D and BAY-I showed equal potency in decreasing cancer cell burden after 4 weeks of treatment (Fig. 2A, B right panel) without significant change the pathological features associated with Pten-null CRPC, including nuclear atypia, loss or partially loss of CK5 basal cells and SMA staining and immune cell infiltration (Fig. 2C and Supplementary Figs. 3D and  4A). Here, KRT5 is linked to cancer.